纳武单抗对晚期HER2阳性肺癌具有显著的抗肿瘤活性。 - Suppr

Dramatic Antitumor Activity of Nivolumab in Advanced HER2-Positive Lung Cancer.

作者信息

Catania Chiara, Passaro Antonio, Rocco Elena Guerini, Spitaleri Gianluca, Barberis Massimo, Noberasco Cristina, Signore Ester Del, Travaini Laura, de Marinis Filippo

机构信息

Thoracic Division, Medical Oncology Department, European Institute of Oncology, Milan, Italy.

出版信息

Clin Lung Cancer. 2016 Sep;17(5):e179-e183. doi: 10.1016/j.cllc.2016.05.004. Epub 2016 Jun 4.

DOI:10.1016/j.cllc.2016.05.004

PMID:27349506

Abstract

摘要

相似文献

Dramatic Antitumor Activity of Nivolumab in Advanced HER2-Positive Lung Cancer.

Clin Lung Cancer. 2016 Sep;17(5):e179-e183. doi: 10.1016/j.cllc.2016.05.004. Epub 2016 Jun 4.

Complete Response Achieved 1 Year after a Single Administration of Nivolumab in a Patient with Lung Adenocarcinoma with Negative Expression of PD-L1.

J Thorac Oncol. 2017 Dec;12(12):e205-e207. doi: 10.1016/j.jtho.2017.08.017.

Positive Conversion of PD-L1 Expression After Treatments with Chemotherapy and Nivolumab.

Anticancer Res. 2017 Oct;37(10):5713-5717. doi: 10.21873/anticanres.12009.

The Significant Antitumor Activity of Nivolumab in Lung Adenocarcinoma with Choriocarcinomatous Features.

Intern Med. 2018 Jun 15;57(12):1773-1777. doi: 10.2169/internalmedicine.0002-17. Epub 2018 Feb 9.

Rapid response to trastuzumab emtansine in a patient with HER2-driven lung cancer.

J Thorac Oncol. 2015 Apr;10(4):e16-7. doi: 10.1097/JTO.0000000000000424.

FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer.

World J Surg Oncol. 2016 Sep 5;14(1):238. doi: 10.1186/s12957-016-0998-y.

Partial response of pulmonary adenocarcinoma with symptomatic brain metastasis to nivolumab plus high-dose oral corticosteroid: a case report.

J Med Case Rep. 2017 Jul 6;11(1):183. doi: 10.1186/s13256-017-1334-z.

Dynamic Adaptation of Tumor Immune Response With Nivolumab Demonstrated by 18F-FDG PET/CT.

Clin Nucl Med. 2018 Feb;43(2):114-116. doi: 10.1097/RLU.0000000000001934.

Durable response to first-line nivolumab in a patient with oligometastatic PD-L1 positive nasopharyngeal cancer.

Oral Oncol. 2018 Dec;87:204-206. doi: 10.1016/j.oraloncology.2018.10.019. Epub 2018 Oct 25.

Advanced Lung Adenocarcinoma with Nivolumab-associated Dermatomyositis.

Intern Med. 2018 Aug 1;57(15):2217-2221. doi: 10.2169/internalmedicine.9381-17. Epub 2018 Mar 9.

引用本文的文献

Genomic and immune characteristics of HER2-mutated non-small-cell lung cancer and response to immune checkpoint inhibitor-based therapy.

Mol Oncol. 2023 Aug;17(8):1581-1594. doi: 10.1002/1878-0261.13439. Epub 2023 Apr 29.

Efficacy of Combination Chemo-Immunotherapy as a First-Line Treatment for Advanced Non-Small-Cell Lung Cancer Patients With HER2 Alterations: A Case Series.

Front Oncol. 2021 Apr 20;11:633522. doi: 10.3389/fonc.2021.633522. eCollection 2021.

Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea.

Cancer Res Treat. 2020 Jan;52(1):292-300. doi: 10.4143/crt.2019.186. Epub 2019 Jul 26.

The Significant Antitumor Activity of Nivolumab in Lung Adenocarcinoma with Choriocarcinomatous Features.

Intern Med. 2018 Jun 15;57(12):1773-1777. doi: 10.2169/internalmedicine.0002-17. Epub 2018 Feb 9.

ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.

J Thorac Oncol. 2017 May;12(5):833-842. doi: 10.1016/j.jtho.2017.01.023. Epub 2017 Feb 4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Dramatic Antitumor Activity of Nivolumab in Advanced HER2-Positive Lung Cancer.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献